Your browser doesn't support javascript.
Graves' disease following administration of second dose of SARS-CoV-2 vaccine.
Goblirsch, Timothy James; Paulson, Ambika E; Tashko, Gerti; Mekonnen, Asefa Jejaw.
  • Goblirsch TJ; Medicine, Georgetown University School of Medicine, Washington, DC, USA tjg58@georgetown.edu.
  • Paulson AE; Medicine, Georgetown University School of Medicine, Washington, DC, USA.
  • Tashko G; Endocrinology, GT Health, Rockville, Maryland, USA.
  • Mekonnen AJ; Sleep Medicine, Rockville Internal Medicine Group, Rockville, Maryland, USA.
BMJ Case Rep ; 14(12)2021 Dec 30.
Article in English | MEDLINE | ID: covidwho-1593626
ABSTRACT
The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves' disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves' disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Graves Disease / COVID-19 Type of study: Case report / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans Language: English Year: 2021 Document Type: Article Affiliation country: Bcr-2021-246432

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Graves Disease / COVID-19 Type of study: Case report / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans Language: English Year: 2021 Document Type: Article Affiliation country: Bcr-2021-246432